Overview

A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of this antibody in participants with rheumatoid arthritis. Part A of the study is an initial dose escalation phase Part B of the study is a randomized allocation of the entire dosing group to parallel treatment assignments
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company